

August 31, 2009
AnGes MG, Inc.

**Project of AnGes MG Subsidiary GenomIdea Adopted as Strategic Basic Technology
Sophistication Supportive Program
– R&D of New Method for Biopharmaceuticals Manufacturing Using Technology to
Maintain Vacuum –**

GenomIdea Inc. (GenomIdea), a subsidiary of AnGes MG, Inc., made a submission concerning the project, R&D of Stabilization Process for Storage of Tailor-Made Biopharmaceuticals Using Technology to Maintain Vacuum, jointly with its affiliates, TSD Japan Inc. (TSD), Amefrec Co., Ltd., Osaka University and National Institute of Advanced Industrial Science and Technology. On August 31, it was announced that this submission was adopted as a project under the Strategic Basic Technology Sophistication Support Program for FY 2009 (Ministry of Economy, Trade and Industry).

GenomIdea and TSD jointly proposed a plan entitled R&D of Processes Facilitating Early Commercialization of New Biopharmaceuticals with High Therapeutic Efficacy, within the framework of Specific R&D Plans under the Law for the Sophistication of Basic Manufacturing Technologies of Small and Medium-Sized Enterprises. This plan was approved by the Kansai Bureau of Economy, Trade and Industry on April 23, 2009. The aim of the recently adopted project is to actually implement this plan by establishing new systems and processes of industrialization applicable for the manufacture of medicines with small batches and multiple varieties such as tailor-made biopharmaceuticals.

Tailor-made pharmaceuticals are expected to provide effective means of treatment even for normally intractable diseases because they allow disease management tailored to the features of individual patients. For the commercialization of biopharmaceuticals, aseptic freeze-drying is usually considered the optimum means of stabilizing the products during storage. However, the aseptic freeze-drying technology currently used for semiconductors and foods is difficult to apply to pharmaceuticals. It is also difficult to utilize the conventional manufacturing technology intended for large-scale and uniformed production of medicines. Against this backdrop, the project will engage in technological assessment and reforms using the drugs for cancer treatment (GEN0101/TSD-0014) currently being developed by GenomIdea and TSD aiming to establish universally applicable technology for storage stabilization suitable for the manufacture of biopharmaceuticals.

The impact of this project on the company's FY 2009 consolidated business performance result is minimal and there will be no revision to the forecast.